Cariprazine: a review in schizophrenia

2018-07-26T22:35:05Z (GMT) by Karly Garnock-Jones
<h5>Compliance with Ethical Standards</h5><h5><i>Funding </i>The preparation of this review was not supported by any external funding.</h5><h5><i>Conflicts of interest </i>Karly Garnock-Jones is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest</h5><h5>Additional information about this Adis Drug Review can be found <a href="">here</a>.<br></h5><div><b>Abstract</b></div><div>Cariprazine (Vraylar™) is a dopamine D3-preferring D2/D3 receptor partial agonist indicated for the treatment of patients with schizophrenia. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the use of cariprazine in patients with this disorder. In 6-week, phase IIb and III trials in patients with schizophrenia, cariprazine was significantly more efficacious than placebo in improving schizophrenia symptoms, including improvements in Positive and Negative Syndrome Scale (PANSS) total scores. It was associated with a significantly longer time to relapse than placebo in a long-term, phase III, relapse-prevention study. Cariprazine was also significantly more efficacious than risperidone in improving PANSS Factor Score for Negative Symptoms in a phase III trial in patients with predominantly negative symptoms of schizophrenia, a typically difficult to treat group of patients. Cariprazine was generally well tolerated in clinical trials, with most adverse events being of mild to moderate severity, and metabolic changes observed were considered generally not clinically significant. Cariprazine is a useful addition to the treatment options for schizophrenia, and may be of particular use in patients with predominantly negative symptoms.<br></div><div><br></div><div><p>© Springer International Publishing AG, part of Springer Nature 2017</p></div>



CC BY-NC 4.0